News

Article

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma

Author(s):

Key Takeaways

  • MediPrint's LL-BMT1 contact lens offers a sustained drug delivery system, potentially improving glaucoma treatment compliance and reducing dosing frequency.
  • The Phase 2b trial showed LL-BMT1's therapeutic equivalence to daily bimatoprost eye drops, highlighting its dosing advantage.
SHOW MORE

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

MediPrint Ophthalmics is advancing its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. The company anticipates meeting with the US Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care. The company notes in its press release that this candidate could significantly reduce treatment burden and enhance patient compliance. The Phase 2b trial demonstrated that LL-BMT1 provided similar therapeutic results as a once-a-week solution to the comparator, 0.01% bimatoprost eye drop, offering a significant dosing advantage over one or multiple-times-per-day eye drop regimens.1

Patent awarded to MediPrint

MediPrint was issued US Patent No. 12,178,904 by the US Patent and Trademark Office on December 31, 2024. This patent covers MediPrint’s proprietary chemistry related to the sustained delivery of prostaglandins from contact lenses and extends the company’s patent protection through 2043. With this issuance, MediPrint’s global patent portfolio encompasses 29 granted patents with additional patents pending.1

Presentation at Glaucoma 360 New Horizons Forum

MediPrint participated in the Glaucoma 360 New Horizons Forum in San Francisco, California on February 7, 2025. The company presented developments in sustained drug delivery technology and discussed how LL-BMT1 could advance the standard of care for patients with glaucoma.1

Reference:
1. MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation. February 7, 2025. Accessed February 12, 2025. https://www.biospace.com/press-releases/mediprint-ophthalmics-advances-glaucoma-program-expands-patent-portfolio-and-prepares-for-key-industry-presentation

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.